Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL737408 | 0.91 | EGLN1 (0.36) | CA1CA2KDM4ELMNAL3MBTL1 | |
| SCHEMBL740369 | 0.90 | CA1 (0.34) | CA1CA2P2RX7KDM4ELMNA | |
| SCHEMBL30233680 | 0.90 | CASP1 (0.39) | KDM4ELMNAL3MBTL1SMN1; SMN2 | |
| SCHEMBL739739 | 0.90 | EGLN1 (0.36) | CA1CA2KDM4ELMNACYP3A4 | |
| SCHEMBL12846265 | 0.90 | HDAC4 (0.38) | HDAC4CA1CA2KDM4EELOVL6 | |
| SCHEMBL738538 | 0.90 | CYP3A4 (0.38) | CA1CA2ELOVL6CYP3A4KMT2A | |
| SCHEMBL15059546 | 0.89 | TTK (0.36) | HDAC4CA1CA2LMNAELOVL6 | |
| SCHEMBL15059547 | 0.89 | TTK (0.36) | HDAC4CA1CA2LMNAELOVL6 | |
| SCHEMBL12846262 | 0.88 | TTK (0.33) | HDAC4CA1CA2KDM4EELOVL6 | |
| SCHEMBL119374 | 0.88 | PTGES (0.35) | CA1CA2KDM4ELMNAELOVL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2024-07-18 | — | — | US | disclosed |
| EP-3473101-B1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS FOR FELINES | INTERVET INT BV (NL) | 2021-05-12 | — | — | EP | disclosed |
| US-20210061775-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2021-03-04 | — | — | US | disclosed |
| EP-3473101-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS FOR FELINES | Intervet International B.V. (NL) | 2019-04-24 | — | — | EP | disclosed |
| US-20180155301-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20160332975-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC. (US) | 2016-11-17 | — | — | US | disclosed |
| US-20150111936-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INC (US) | 2015-04-23 | — | — | US | disclosed |
| EP-2545777-A1 | Isoxazoline compositions and their use as antiparasitics | Intervet International B.V. (NL) | 2013-01-16 | — | — | EP | disclosed |
| US-20110059988-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | INTERVET INTERNATIONAL B.V. | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160332975-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | HDAC4 504/4885CA1 1771/4885CA2 651/4885 |
| US-20210061775-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | HDAC4 504/4885CA1 1771/4885CA2 651/4885 |
| US-20180155301-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | HDAC4 504/4885CA1 1771/4885CA2 651/4885 |
| US-20150111936-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, EPX | HDAC4 459/4885CA1 1649/4885CA2 595/4885 |
| US-20240239759-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, TUBA1C | HDAC4 504/4885CA1 1771/4885CA2 651/4885 |
| US-20110059988-A1 | ISOXAZOLINE COMPOSITIONS AND THEIR USE AS ANTIPARASITICS | PRDX5, TUBA3C, AADAC | HDAC4 411/4885CA1 1922/4885CA2 661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.